Authors
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
Targeting Leptomeningeal Brain Tumors With CAR T TherapyManuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.
Latest:
Potential of NK Cells in Multiple Myeloma: Nina Shah, MDThe hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential utility of natural killer cells in multiple myeloma.
Latest:
Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCLJohn M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Michael Wang, MD, on Liso-Cel's Approval in Mantle Cell LymphomaThe professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center discussed the advantages the newly approved CAR-T has for older, frailer patients.
Latest:
Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic MalignanciesPaul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.
Latest:
Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, LymphomasMatthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.
Latest:
CAR T-Cell Therapy Transforms Leukemia and Lymphoma Treatment, But Toxicity Concerns RemainOlalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.
Latest:
Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in LymphomaDimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Nilanjan Ghosh, MD, PhD, on Paving the Way for CAR T Therapies in LymphomasThe chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.
Latest:
Dr. Vesole on Developing Off-the-Shelf CAR T-Cell Therapy in Multiple MyelomaDavid H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy products in multiple myeloma.
Latest:
Noopur Raje, MD, on bb21217 Data in R/R Multiple MyelomaThe director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.
Latest:
Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in OncologyMiguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Latest:
TILs, the Ultimate in Personalized Immunotherapy, Move Closer to MarketNovember 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.
Latest:
Making Progress Against Relapsed/ Refractory DLBCL Without CAR TA panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.
Latest:
Brexucabtagene Autoleucel in R/R Mantle Cell LymphomaExperts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Latest:
Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 TrialThe goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Ruan on Future Research With CAR T-Cell Therapy in MCLJia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Jason Westin, MD, FASCP, on the Potential Impact of Predicting Toxicity for CAR-T TreatmentThe director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed axi-cel's safety profile and an important factor for improving access to CAR-T therapies.
Latest:
Reinfusion of CAR T Therapy Shows Promise in B-ALLLong term survival was limited and all patients with B-cell acute lymphoblastic leukemia eventually relapsed.
Latest:
Nadofaragene Firadenovec Sustains Efficacy in BCG-Unresponsive NMIBC SubgroupsThe efficacy of the novel intravesical gene-mediated therapy nadofaragene firadenovec was sustained across subgroups of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.
Latest:
Durable Response Seen With Axi-Cel in Non-Hodgkin LymphomaIn this population, median progression-free survival was nearly 40 months.
